Company Information

  

Address: 405 EAGLEVIEW BOULEVARD  
City: EXTON 
State: PA 
Zip Code: 19341 
Telephone: 484-713-6000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Our distinctive approach to personalized biologics is based on our proprietary autologous fibroblast technology. Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. We target the underlying cause of disease by using fibroblast cells from a patient's skin and genetically modifying them to create localized therapies that are compatible with the unique biology of the patient (i.e., which are autologous).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-21.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.54
Net Inc/Total Assets-0.84Total Liab/Inv Cap0.69
Net Inc/Inv Cap-1.08Total Liab/Comm Equity0.06
Pretax Inc/Net SalesNAInterest Coverage Ratio-18.61
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/Equity0.35
SG&A/NetSalesNATotal Debt/Equity0.35
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio4.05
Inventory TurnoverNACurrent Ratio4.05
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold 0.00 0.00 0.00 0.00
Selling & Admin Exps 1.64 1.64 1.96 1.67
Operating Income -2.98 -4.90 -4.60 -5.03
Interest Exp 0.19 0.19 0.27 0.19
Pretax Income -2.90 2.90 -0.12 -14.02
Other Income 0.27 7.99 4.75 -8.81
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.90 2.90 -0.12 -14.02

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 12.20 17.42 11.91 15.91
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 12.70 17.90 12.18 16.35
Net Property, Plant & Equipment 1.41 1.47 1.54 1.53
Total Assets 14.15 19.41 13.78 17.97
Liabilities        
Accounts Payable 1.89 4.43 3.35 3.11
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 1.89 4.43 3.47 3.42
Long-Term Debt 3.20 3.14 1.44 1.19
Total Liabilities 7.89 10.40 17.11 21.41
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.02 0.02
Retained Earnings -181.70 -178.80 -181.70 -181.59
Treasury Stock NA NA NA NA
Total Stockholders' Equity 6.26 9.01 -3.33 -3.44
Total Liabilities and Stockholders' Equity 14.15 19.41 13.78 17.97

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -4.76 -4.16 -3.90 -4.23
Net Cash Provided by Investing Activities -0.04 -0.09 -0.11 -0.16
Net Cash Provided by Financing Activities -0.42 9.75 0.00 -0.26

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.20-31.55--
12/20140.18-25.65--
12/20150.49-34.45--
12/20160.36-15.29--
12/20170.00-16.24--
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18372,14723.06




Report Date : 7/9/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.